Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2006;114:e537
doi: 10.1161/CIRCULATIONAHA.106.626184
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dart, A. M.
Right arrow Articles by Kingwell, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dart, A. M.
Right arrow Articles by Kingwell, B.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*AMLODIPINE BESYLATE
*ATENOLOL
Related Collections
Right arrow Clinical Studies

(Circulation. 2006;114:e537.)
© 2006 American Heart Association, Inc.


Correspondence

Letter by Dart et al Regarding Article, "Differential Impact of Blood Pressure-Lowering Drugs on Central Aortic Pressure and Clinical Outcomes: Principal Results of the Conduit Artery Function Evaluation (CAFE) Study"

Anthony M. Dart, MD, PhD

Department of Cardiovascular Medicine, Alfred Hospital, Melbourne, Australia, a.dart{at}alfred.org.au

Christoph D. Gatzka, MD

University of Melbourne, Melbourne, Australia

Bronwyn Kingwell, PhD

Baker Heart Research Institute, Melbourne, Australia

To the Editor:

We read with interest the recent article from the Conduit Artery Function Evaluation (CAFE) investigators1 on estimated central aortic blood pressure. The use of central arterial waveforms and estimates of central pressures in routine clinical practice would be justified if such measures materially add to the prognostic information provided by "routine" blood pressure measures, most usually obtained from brachial artery sphygmomanometry. The results from CAFE confirm our own recent findings from a substudy of The Australian National Blood Pressure Study 2 (ANBP2) 2 showing that this is not the case.3 In our study, neither central augmentation index nor central systolic or pulse pressure was a significant predictor of outcome, whereas brachial systolic and pulse pressures were. Diastolic pressure was not related to outcome in our study. In the CAFE study,1 central pulse pressure was either less predictive than brachial pulse pressure or of approximately similar predictive value. Augmentation index was not predictive of outcome in 2 of the 3 adjusted models. No information is provided regarding the predictive value of diastolic pressure.

There are several differences in the 2 studies that may account for the fact that central pressures and waveforms were of no predictive value in our cohort. Our study was in women, who only made up about 20% of the CAFE cohort. In our study, we did not include development of renal impairment as an end point, as they did in CAFE. The rationale for including this, a component of the tertiary end point of the parent Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) study,4 is unclear, as it is not obvious that estimated proximal aortic pressure would provide a good estimate of renal artery pressures. We would be interested to know how central pressures and augmentation index were related to the primary and secondary end points of the ASCOT study. In our study,2 all central pressure and waveform data were collected before treatment rather than during treatment, as in CAFE. Furthermore, we recorded carotid waveforms, whereas in CAFE, a radial waveform was used and transformed to give a putative central aortic pressure. It is interesting that despite the differences in study design, brachial pulse pressure, measured before treatment in our study and during treatment in CAFE, was similarly related to risk, with a hazard ratio of 1.19 (per 10 mm Hg) in our study and 1.23 in the CAFE study.

We concur with the editorial5 accompanying the CAFE study that the technique of radial tonometry is "not yet ready for prime time" (p 1163) in routine clinical practice, but we believe that along with other methods for assessing central arterial parameters, it should remain an area of active research.


*    Acknowledgments
 
Disclosures

Drs Dart and Kingwell have received NHMRC grants. Dr Gatzka reports no disclosures.


*    References
up arrowTop
*References
 

  1. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O’Rourke M. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) Study. Circulation. 2006; 113: 1213–1225.[Abstract/Free Full Text]
  2. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown A, Jennings GL, Johnston CI, McNeil JJ, Macdonald GJ, Marley JE, Morgan TO, West MJ. A comparison of outcomes with angiotensin-converting–enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003; 348: 583–592.[Abstract/Free Full Text]
  3. Dart AM, Gatzka CD, Kingwell BA, Willson L, Cameron JD, Liang Y-L, Berry KL, Wing LMH, Reid CM, Ryan P, Beilin LJ, Jennings GL, Johnston CI, McNeil JJ, MacDonald GJ, Morgan TO, West MJ. Brachial blood pressure but not carotid arterial waveforms predict cardiovascular events in elderly female hypertensives. Hypertension. 2006; 47: 785–790.[Abstract/Free Full Text]
  4. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O’Brien E, Ostergren J. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005; 9489: 895–906.
  5. Oparil S, Izzo JL. Pulsology rediscovered: commentary on the conduit artery function evaluation (CAFE) Study. Circulation. 2006; 113: 1162–1163.[Free Full Text]




This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dart, A. M.
Right arrow Articles by Kingwell, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dart, A. M.
Right arrow Articles by Kingwell, B.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*AMLODIPINE BESYLATE
*ATENOLOL
Related Collections
Right arrow Clinical Studies